Caili Xu
Shanghai, 201203, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Development of an anti-LAIR1 antibody-drug conjugate for acute myeloid leukemia therapy.
Journal: International journal of biological macromolecules
Published: October 26, 2024
Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8+ T cell and evading IL-18BP in preclinical models.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: October 15, 2024
Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 31, 2024
Rubicon siRNA-encapsulated liver-targeting nanoliposome is a promising therapeutic for non-alcoholic fatty liver disease.
Journal: International journal of pharmaceutics
Published: July 09, 2024
Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: December 02, 2023
TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer.
Journal: Journal of nanobiotechnology
Published: August 24, 2023
Editorial: Community series in combinational immunotherapy of cancer: novel targets, mechanisms, and strategies, volume II.
Journal: Frontiers in immunology
Published: July 11, 2023
Innate Immunity in Cancer Biology and Therapy.
Journal: International journal of molecular sciences
Published: May 21, 2023
Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma.
Journal: Immunotherapy
Published: February 02, 2023
Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.
Journal: Frontiers in immunology
Published: July 27, 2022
Last Updated: 09/26/2026